OFP EXTRA OSCE Q1 - Trigeminal Neuropathic Pain

Worked answers for OFP EXTRA OSCE — Question 1.

Scenario

Margaret is a 48 year old female who underwent surgical extraction of her lower right third molar eight months ago. In the weeks following the procedure she developed a persistent burning and shooting pain along the right mandibular nerve distribution, extending from the extraction site toward the right chin and lower lip. The pain has not resolved and is consistent with a diagnosis of trigeminal neuropathic pain.

Questions (each sub-question = 3 marks; total = 21 marks)

1. List 3 possible aetiologies associated with trigeminal neuropathic pain. (3 marks)
2. Describe the key clinical features that distinguish trigeminal neuropathic pain from other orofacial pain conditions. (3 marks)
3. Describe your diagnostic approach and the investigations required to confirm a diagnosis of trigeminal neuropathic pain. (3 marks)
4. List 3 pharmacological agents used in the management of trigeminal neuropathic pain. (3 marks)
5. Identify 3 psychosocial factors relevant to the management of this patient. (3 marks)
6. List 3 non-pharmacological strategies that may be used in the management of trigeminal neuropathic pain. (3 marks)
7. Outline 3 potential complications or challenges encountered in the long-term management of trigeminal neuropathic pain. (3 marks)

What is neuropathic pain?

Neuropathic pain is pain caused by a lesion or disease of the somatosensory nervous system (an abnormally functioning system), in contrast to nociceptive pain which arises from a normally functioning system responding to tissue damage. Margaret’s presentation fits post-traumatic trigeminal neuropathic pain (PTTN) — unilateral pain following and caused by trauma to the trigeminal nerve, persisting >3 months.¹

1. List 3 possible aetiologies associated with trigeminal neuropathic pain

Trigeminal neuropathic pain follows a lesion of a trigeminal nerve branch. Most cases in dental practice are post-traumatic (PTTN), but other aetiologies exist. Any 3:

• Post-dental/surgical trauma — lower third molar surgery is the most common cause; also dental implants, orthognathic surgery, mid-face fractures, root canal therapy, and local anaesthetic injections (incidence of trigeminal injury ~3–5%).¹
• Direct surgical trauma to the IAN or lingual nerve during the extraction — sectioning, compression/traction by elevators or retractors, thermal injury from drilling without irrigation, or stretching during forceful elevation.²
• Secondary nerve compression or chemical injury — post-operative haematoma compressing the nerve, or intra-neural deposition of local anaesthetic; anatomical proximity of root apices to the IAN canal is a predisposing risk factor.²
• Post-macrotrauma (e.g. road traffic accident / blunt facial trauma) or
• painful trigeminal neuropathy attributed to acute herpes zoster (post-herpetic).¹³
• Trigeminal postherpetic neuralgia
• Idiopathic painful trigeminal neuropathy

2. Describe the key clinical features that distinguish trigeminal neuropathic pain from other orofacial pain conditions

Any 3 distinguishing features:

• Persistence beyond the expected healing period (typically >3 months post-procedure) — pain that no longer serves a protective role and does not resolve with socket healing.²
• Neuropathic character — burning, aching, shooting, or electric-shock-like pain; moderate to severe; usually continuous and present on most days, but may be paroxysmal or mixed.²³
• Clear preceding traumatic event (e.g. the extraction) within ~6 months of onset that plausibly caused the nerve injury.²¹
• Anatomically confined and unilateral — maps to the dermatome of the affected nerve (here the IAN: lower lip, chin, mandibular teeth, adjacent gingiva), rarely crosses the midline, though it may become more diffuse over time.²³
• Mixed positive and negative sensory signs — positive: allodynia (pain from a normally non-painful stimulus), hyperalgesia, dysaesthesia/paraesthesia; negative: hypoaesthesia/numbness or hypoalgesia.²³
• Absence of identifiable local dental pathology — no infection, retained root fragment, or other odontogenic cause that explains the pain.²

3. Describe your diagnostic approach and the investigations required to confirm a diagnosis of trigeminal neuropathic pain

PTTN is largely a clinical diagnosis built on history, examination, and sensory testing, with imaging used to exclude local pathology. Approach (any combination):

Initial clinical assessment²

• Detailed pain history — onset/timeline relative to the procedure, character/quality, severity (NRS 0–10), distribution, and aggravating/relieving factors.
• Comprehensive intraoral examination — inspect the extraction socket for infection/dry socket/healing complications and assess adjacent teeth and soft tissues.
• Cranial nerve sensory examination — bedside testing of the IAN and lingual nerve territories using light touch, pin-prick, and two-point discrimination.
• Medical/medication history and psychosocial assessment — impact on sleep, daily activity, study, social function, and emotional wellbeing; review prior investigations and treatments.

Special investigations²³

• Panoramic radiograph (OPG) — assess the healing socket, exclude retained root fragments/instruments and bony pathology, and review the IAN canal relationship.
• CBCT — greater anatomical detail of the IAN canal and any nerve penetration; MRI (less common) to rule out tumours/central pathology.
• Quantitative sensory testing (QST) / sensory mapping — objectively characterise the sensory deficit and detect allodynia/hyperalgesia. Where QST equipment is unavailable, dental instruments can be adapted (probe for pin-prick, warm/cool instruments for thermal, cotton wool for mechanosensation); affected areas should be mapped, marked, and photographed for documentation and follow-up.

ICHD-3 / ICOP diagnostic criteria for painful post-traumatic trigeminal neuropathy

A. Facial and/or oral pain in the distribution(s) of one or both trigeminal nerves, fulfilling criterion C. B. History of an identifiable traumatic event to the trigeminal nerve(s), with clinically evident positive (hyperalgesia, allodynia) and/or negative (hypoaesthesia, hypoalgesia) signs of trigeminal nerve dysfunction. C. Evidence of causation — pain is localised to the distribution of the affected nerve AND has developed <6 months after the traumatic event. D. Not better accounted for by another ICHD-3 diagnosis (most trigeminal nerve injuries do not result in pain).³

4. List 3 pharmacological agents used in the management of trigeminal neuropathic pain

Any 3 classes (with examples):

• Tricyclic antidepressants (TCAs) — e.g. amitriptyline, nortriptyline; first-line, act via noradrenergic/serotonergic pathways.²
• Gabapentinoids — e.g. gabapentin, pregabalin; act on voltage-gated calcium channels to reduce central sensitisation.²
• Anticonvulsants (sodium-channel blockers) — e.g. carbamazepine, oxcarbazepine; particularly useful for electric-shock-like sensations.²
• SNRIs — e.g. duloxetine, venlafaxine — and topical agents (lidocaine 5% patch/gel or capsaicin) are further options.²

5. Identify 3 psychosocial factors relevant to the management of this patient

PTTN carries a substantial psychosocial burden, and patients with more severe pain show greater psychological impact; quality of life and emotional problems can be predicted by pain intensity.³ Any 3:

• Depression / low mood — elevated in patients with more severe pain, and a perpetuating biopsychosocial factor.³¹
• Pain catastrophising — thinking of the worst-case scenario; a recognised vulnerability predictor that worsens prognosis.³¹
• Reduced quality of life and coping efficacy — pain interferes with sleep, work/study, and social function, and reduced coping efficacy perpetuates the chronic pain cycle.³
• Other contextual stressors — anxiety, life/work stressors, active compensation or medico-legal claims, and the patient’s expectations (e.g. seeking a “dental fix”), all of which influence management and adherence.¹

6. List 3 non-pharmacological strategies that may be used in the management of trigeminal neuropathic pain

Any 3:

• Patient education and reassurance — explain the neuropathic mechanism and set realistic expectations (a 50% pain reduction is a clinical success; 100% cure is rare).²¹
• Cognitive-behavioural therapy (CBT) and pain neuroscience education — address catastrophising and the Axis II psychosocial component of chronic pain.²¹
• Orofacial physiotherapy / sensory re-education and TENS (transcutaneous electrical nerve stimulation).²
• Mindfulness-based stress reduction (MBSR) or acupuncture as adjunctive strategies.²¹

7. Outline 3 potential complications or challenges encountered in the long-term management of trigeminal neuropathic pain

Any 3 — all genuinely supported by the lecture and textbook:

• Poor prognosis / progression to refractory chronic pain — PTTN is characterised by a poor outcome: improvement is seen in fewer than one-third of patients and only 10–20% report significant improvement, while about half report no improvement or worsened pain, with some pain persisting even ~13 years after onset. Central sensitisation drives this refractory course.³¹
• Limited and side-effect-laden response to pharmacotherapy — PTTNs are among the most recalcitrant neuropathic pains; effective relief often requires high drug doses producing significant side effects, and only ~20–40% of patients attain meaningful (≥30%) pain relief, so efficacy must be balanced against tolerability and tolerance.³¹
• Risk of iatrogenic worsening from further dental intervention — failure to recognise the neuropathic diagnosis can lead to repeated, irreversible treatment (RCTs, extractions, implants) that worsens the pain; irreversible dental treatment should be avoided where no obvious dental cause is identified.¹
• Sustained psychosocial disability — ongoing depression, catastrophising, impaired quality of life, and reduced function/sleep complicate long-term care and require multidisciplinary management.³¹
• Narrow window for improvement / incomplete sensory recovery — referral after 12 months significantly reduces the chance of improvement, and sensory deficits may be permanent (neuropraxia recovers best; axonotmesis/neurotmesis worse).¹

Footnotes

1. L34 Neuropathic Orofacial Pain including Burning Mouth Syndrome. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵

2. OFP Mock Formative Q1 - Post-Traumatic Trigeminal Neuropathic Pain_integrated — marking key. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶ ↩¹⁷ ↩¹⁸

3. 43 Neuropathic Orofacial Pain (Contemporary Oral Medicine). ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³